Animal experiment:

Mice: To confirm that AZD2932 has similar potency against both PDGFβ and VEGFR-2 phosphorylation, the female nude mice bearing C6 tumors are dosed iv with VEGF-A and PDGFBB 5 min prior to cull and 6 h post last dose of AZD2932 and the lungs excised immediately after. Lung lysates are analyzed by western blot for total and phosphorylated VEGFR-2 and PDGFβ[1].

AZD2932 is a potent inhibitor for multiple protein tyrosine kinases (IC50 = 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.) [1]

VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases. It mediates in various cellular functions, including endothelial proliferation, migration, survival, tubular morphogenesis and sprouting. PDGFR are platelet-derived growth factor receptors that exhibit intracellular tyrosine kinase activity. It involves in embryonic development, angiogenesis, proliferation and differentiation etc.

AZD2932 has a potent and balanced profile against PDGFR, VEGFR-2, Flt-3 and c-Kit (IC50: 0.009). It also has a good fraction unbound between 3.3% free in human and 7.0% in dog sera and has no activity against hERG. [1]

In female nude mice bearing C6 tumors, AZD2932 treatment at 3–50 mg/kg b.i.d. 10 h apart give 60–80% inhibition of both p-VEGFR-2 and p-PDGFRb in a 1:1 ratio. [1]

Reference:
1.  Plé PA, Jung F, Ashton S, Hennequin L et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6.